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ABSTRACT: Preventing orthopedic implant-associated bacterial infections remains a
critical challenge. Current practices of physically blending high-dose antibiotics with
bone cements is known for cytotoxicity while covalently tethering antibiotics to implant
surfaces is ineﬀective in eradicating bacteria from the periprosthetic tissue environment
due to the short-range bactericidal actions, which are limited to the implant surface.
Here, we covalently functionalize poly(ethylene glycol) dimethacrylate hydrogel
coatings with vancomycin via an oligonucleotide linker sensitive to Staphylococcus
aureus (S. aureus) micrococcal nuclease (MN) (PEGDMA-Oligo-Vanco). This design
enables the timely release of vancomycin in the presence of S. aureus to kill the bacteria
both on the implant surface and within the periprosthetic tissue environment. Ti6Al4V
intramedullary (IM) pins surface-tethered with dopamine methacrylamide (DopaMA)
and uniformly coated with PEGDMA-Oligo-Vanco eﬀectively prevented periprosthetic
infections in mouse femoral canals inoculated with bioluminescent S. aureus. Longitudinal bioluminescence monitoring, μCT
quantiﬁcation of femoral bone changes, end point quantiﬁcation of implant surface bacteria, and histological detection of S.
aureus in the periprosthetic tissue environment conﬁrmed rapid and sustained bacterial clearance by the PEGDMA-Oligo-Vanco
coating. The observed eradication of bacteria was in stark contrast with the signiﬁcant bacterial colonization on implants and
osteomyelitis development found in the absence of the MN-sensitive bactericidal coating. The eﬀective vancomycin tethering
dose presented in this on-demand release strategy was >200 times lower than the typical prophylactic antibiotic contents used in
bone cements and may be applied to medical implants and bone/dental cements to prevent periprosthetic infections in high-risk
clinical scenarios. This study also supports the timely bactericidal action by MN-triggered release of antibiotics as an eﬀective
prophylactic method to bypass the notoriously harder to treat periprosthetic bioﬁlms and osteomyelitis.
■ INTRODUCTION
Periprosthetic infections represent occasional but serious
health threats. Bacterial colonization around implants and
subsequent bioﬁlm formation are diﬃcult to treat and could
lead to implant failure, requiring major revision surgeries
associated with high treatment cost, high morbidity, and even
mortality.1−3 There are no eﬀective strategies for eradicating
established bioﬁlms or bacteria harboring within dense tissues
such as the canaliculi of bone due to poor penetration of
antibiotics and immune cells into the dense matrices of bioﬁlm
and cortical bone.4−7 Thus, prophylactic strategies, particularly
in high-risk patient populations and/or following high-risk
clinical procedures, that ensure timely elimination of bacteria
within the implant microenvironment thereby preventing
bioﬁlm formation or bacteria invasion into bone canaliculi
would be highly desired.
A current clinical practice for preventing infections in high-
risk orthopedic joint replacement surgeries involves physical
blending of antibiotics with bone cements. This approach,
however, requires high antibiotic loading that could exert local
and systemic cytotoxicity. Delivering antibiotics via non-
covalent implant surface coatings has been pursued as a safer
alternative,8,9 although achieving suitable antibiotic release
kinetics to ensure adequate and prompt release remains a
challenge.8,10−15 Antibiotics covalently attached to implant
surfaces4,16,17 have also been shown to exert bactericidal
properties when they are presented via linkers or polymer
chains of suitable ﬂexibility/lengths18,19 at a modiﬁcation site
minimally perturbing the bioactivity of the drug.20 A limitation
of this covalent surface modiﬁcation approach, however, is that
the antibiotic action is restricted to the immediate surface of
the implant. For instance, we recently demonstrated that
vancomycin covalently conjugated to the polymer brushes
grafted from Ti6Al4V intramedullary (IM) pins was able to
signiﬁcantly reduce the colonization/growth of Staphylococcus
aureus (S. aureus) on the metallic implant surface.21 Complete
eradication of bacteria within the periprosthetic IM tissue
environment, however, was not achieved due to the inability of
the covalently tethered vancomycin to diﬀuse away from the
Ti6Al4V surface.
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We envision that the covalent attachment of antibiotics to
the implant surface via a linker sensitive to unique bacterial
enzymatic activities could bridge the gap among the existing
approaches. The timely on-demand release of free antibiotics
from covalently modiﬁed implant surfaces could help combat
infections within a broader periprosthetic tissue microenviron-
ment while mitigating cytotoxicity associated with the burst
release of high doses of physically entrapped antibiotics or risks
for developing bacteria resistance due to inadequate/delayed
antibiotic releases.18,22 Various advanced drug delivery systems
utilizing external stimuli such as pH, temperature, magnetic
ﬁeld, and ultrasound to trigger drug release were devel-
oped.23−27 More recently, endogenous enzymatic activities
(especially proteases and nucleases) have been exploited as
more biologically relevant and safer alternatives to stimulate
on-demand drug release from peptide- and nucleotide-based
delivery systems.23 Nonspeciﬁc cleavages of the peptide and
oligonucleotide in these systems, however, present barriers to
the success of this approach. Oligonucleotide sequences with
2′-O-carboxymethyl modiﬁcations were recently shown to
improve cleavage speciﬁcity27 by micrococcal nucleases (MNs)
of S. aureus, the Gram-positive bacterium responsible for a
third of all orthopedic implant related infections and a major
cause of osteomyelitis.3 The therapeutic eﬃcacy of the MN-
triggered release of physically entrapped vancomycin in silica
nanocapsules was demonstrated in vitro.28,29 However, in vivo
eﬃcacy of this approach, especially in the context of on-
demand release of covalently tethered antibiotics for combat-
ing periprosthetic infections, is unknown.
Here, we covalently functionalize PEGDMA hydrogel with
vancomycin via a 2′-O-carboxymethyl modiﬁed oligonucleo-
tide linker sensitive to S. aureus MN and evaluate its
antibacterial activity in vitro and antiperiprosthetic infection
properties in vivo upon application to metallic implants as a
surface coating using a rodent femoral canal infection model.
The oligonucleotide linker (abbreviated as oligo, Figure 1a)
consists of a carboxylic acid and an acrydite on either end of
the mC−mG−T−T−mC−mG sequence, which was previ-
ously shown to exhibit enhanced stability to mouse and human
serum but sensitivity to S. aureus MN cleavages.28−30 The
acrydite end is used to covalently conjugate the probe to the
PEGDMA matrix during radical polymerization (Figure 1b)
while the carboxylic acid end of the oligo linker is used to form
an amide linkage with the N-vancosaminyl group of
vancomycin via EDC/NHS chemistry (Figure 1c). Vancomy-
cin, a glycopeptide antibiotic acting at the Gram-positive
bacterial cell walls to block peptidoglycan synthesis, is
considered the most eﬀective in treating infections caused by
Figure 1. Depiction of the PEGDMA-Oligo-Vanco hydrogel network and MN-triggered vancomycin release. (a) Oligonucleotide (Oligo) sequence
modiﬁed with bifunctional end groups. (b) PEGDMA-Oligo hydrogel formation. (c) PEGDMA-Oligo-Vanco hydrogel formation and MN-
triggered vancomycin release.
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Staphylococcus including Methicillin-resistant S. aureus.31 It
inhibits the transpeptidation and transglycosylation steps of
bacterial cell wall biosynthesis through the binding of the L-
Lys−D-Ala−D-Ala termini of the nascent peptidoglycan
precursor through H-bonds. Chemical modiﬁcation at the N-
vancosaminyl site is known to present minimal perturbation to
this binding.32,33 The ﬂexible C5 spacers between the
nucleotide sequence and the bifunctional end groups are
designed to relieve steric hindrance during amidation with
vancomycin via the N-vancosaminyl site and to ensure
adequate rotational freedom of the oligo upon covalent
attachment to the hydrogel matrix. In the presence of
metabolically active S. aureus, the bacterial MN is expected
to cleave the oligo at the unmodiﬁed T−T position, releasing
the vancomycin with a small overhung fragment at the N-
vancosaminyl site (Figure 1c). We recently showed that the
minimal eﬀective concentration of vancomycin (against S.
aureus) was not signiﬁcantly altered upon modiﬁcation with an
N-vancosaminyl oligo(ethylene glycol) overhang,21 which is of
comparable length of the amidated oligo fragment overhang
upon MN cleavage.
■ RESULTS AND DISCUSSION
Synthesis of PEGDMA-Oligo and PEGDMA-Oligo-
Vanco Hydrogels. We ﬁrst validated the cleavage of the
oligo probe (synthesized and puriﬁed by Integrated DNA
Technologies) by MN (source: S. aureus strain ATCC 27735;
Worthington Biochemical Corporation) prior to its conjuga-
tion with vancomycin or PEGDMA hydrogel. Gel permeation
chromatography (GPC) and UV detection at 260 nm revealed
two fragments upon treatment of the oligo by MN (0.1 U/μL)
in PBS (pH 7.4, 10 mM) containing a physiological
concentration of calcium ions (Figure 2a, blue trace). In the
absence of calcium ions, MN showed very little cleavage of
oligo (Figure 2a, red trace).
Upon conﬁrmation of the sensitivity of the oligo to MN
cleavage, it was covalently incorporated with PEGDMA during
photopolymerization. A leaching experiment showed that 90 ±
5.0% oligo was eﬀectively tethered to a 15 w/v% PEGDMA
hydrogel, achieving 1.1 μg oligo/mg PEGDMA incorporation
content, as revealed by the detection of untethered oligo
(absorption at 260 nm) leached into deionized (DI) water
upon extensive equilibration of the PEGDMA-Oligo hydrogel
in PBS (48 h).
Covalent attachment of vancomycin to PEGDMA-Oligo
hydrogel was carried out using EDC/NHS chemistry resulting
in the PEGDMA-Oligo-Vanco hydrogel. To examine the
release of covalently tethered vancomycin from the hydrogel,
PEGDMA-Oligo-Vanco hydrogel discs (50 μL, 8 mm in
diameter, n = 3) were incubated in PBS (pH 7.4, 10 mM)
containing a physiological concentration of calcium ions with
or without the presence of MN (0.1 and 1.0 U/μL). The
concentration of released vancomycin was monitored by UV
spectroscopy at 280 nm. As shown in Figure 2b, the release of
vancomycin was only detected in the groups spiked with MN,
supporting cleavage of the oligo linker and release of
vancomycin by MN activity. The initial release (ﬁrst 4 h) of
vancomycin was slightly higher with the higher MN
concentration, although the total vancomycin released over
24 h was the same. Assuming complete release of vancomycin
after 24 h, the amount of vancomycin loaded on the 15 w/v%
PEGDMA hydrogel matrix was 90 μg/mm3 hydrogel (or 24
mg Vanco/40 g PEGDMA; note that the minimum inhibitory
concentration of vancomycin was ∼2 μg/mL21). This
vancomycin covalent loading content was signiﬁcantly lower
than the noncovalent prophylactic antibiotics incorporation
content in commercial bone cement (e.g., 0.5−1.0 g
gentamycin/40 g bone cement, 1.0 g tobramycin/40 g bone
cement).34−37
In Vitro Antibacterial Activity of PEGDMA-Oligo-
Vanco Hydrogel. The therapeutic eﬃcacy of PEGDMA-
Oligo-Vanco hydrogel was ﬁrst evaluated by in vitro bacterial
cultures. PEGDMA-Oligo-Vanco and PEGDMA-Oligo hydro-
gel discs (50 μL, 8 mm in diameter, n = 3) were incubated in
Luria−Broth (LB) containing 130 CFU of S. aureus at 37 °C.
To account for potential contribution from residue uncon-
jugated vancomycin, another control group with the same
content of vancomycin physically entrapped (without EDC/
NHS) at the time of PEGDMA-Oligo hydrogel formation was
also prepared (PEGDMA-Oligo/Vanco). All hydrogels were
washed for 72 h in DI water before being placed in Xen-29 S.
aureus suspension culture. The Xen29 S. aureus, emitting
bioluminescence when metabolically active due to the
expression of luciferase,38 enables convenient visualization in
vitro and longitudinal monitoring in vivo by an in vivo imaging
system (IVIS-100, PerkinElmer). As shown in Figure 2c, the
PEGDMA-Oligo-Vanco hydrogel was able to signiﬁcantly
inhibit the bacterial growth by 8-fold after 48 h. Of note, IVIS
imaging showed no signs of bacterial attachment and
colonization on the surface of the PEGDMA-Oligo-Vanco
hydrogel upon its retrieval from the suspension culture after 48
Figure 2. MN-triggered oligo cleavage and the antibacterial activities
of PEGDMA-Oligo-Vanco hydrogel in vitro. (a) GPC traces of intact
oligo (black) and oligo upon treatment with MN with (blue) and
without (red) Ca2+. (b) Cumulative vancomycin (Vanco) release
from PEGDMA-Oligo-Vanco hydrogel incubated with (black and
blue) and without (red) MN. Diﬀerences at all given time points were
signiﬁcant (p ≤ 0.0001). (c) Total bacterial counts after 24 and 48 h
of Xen-29 S. aureus culture in LB media containing PEGDMA-Oligo-
Vanco, washed PEGDMA-Oligo/Vanco, or PEGDMA-Oligo hydro-
gels (n = 3; inset, corresponding IVIS image of the PEGDMA-Oligo-
Vanco and PEGDMA-Oligo hydrogels retrieved after 48 h in S. aureus
culture). (d) Photograph (left) and IVIS image (right) of an LB agar
plate of Xen-29 S. aureus culture 24 h after placement of PEGDMA-
Oligo-Vanco and PEGDMA-Oligo hydrogel discs (n = 2 shown) over
the agar plate. Error bars represent standard deviations. * p ≤ 0.05, **
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 (two-way ANOVA).
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h whereas signiﬁcant colonization of S. aureus was detected on
the PEGDMA-Oligo control hydrogel (Figure 2c, inset). The
cleavage of the oligo linker by live S. aureus and the ability of
released vancomycin to diﬀuse out of the hydrogel to exert
antibiotic activities were further validated by the clear zone
development around the PEGDMA-Oligo-Vanco hydrogels
placed on an agar plate of the S. aureus culture. No clear zone
was developed around the PEGDMA-Oligo control. These in
vitro outcomes suggest that, when applied to the surface of
implants, the PEGDMA-Oligo-Vanco hydrogel coating may
also inhibit S. aureus surface attachment and colonization and
suppress or even eradicate bacterial growth in its vicinity.
Hydrogel Coating of Ti6Al4V IM Pins. To evaluate the
ability of PEGDMA-Oligo-Vanco hydrogel coating to prevent
or mitigate periprosthetic infections in vivo, we applied the
coating to the surface of Ti6Al4V IM pins emulating the
metallic hardware used in orthopedic surgeries. To enhance
the adhesion and stability of the hydrogel coating to the
metallic substrate, the Ti6Al4V surface was ﬁrst treated with
dopamine methacrylate (DopaMA, Figure 3a). The catechol
group from DopaMA is known for high aﬃnity for surface
oxides of Ti6Al4V39 whereas the methacrylate is designed to
covalently polymerize with the PEGDMA matrix during
hydrogel coating application. Dip-coating the metallic substrate
with DopaMA is expected to promote a more uniform and
stable surface coating of the functionalized PEGDMA. The
choice of the methacrylate surface group also makes it possible
to covalently bond with poly(methyl methacrylate) (PMMA)
bone cement if desired. Successful surface modiﬁcation of
Ti6Al4V plates (1 cm × cm) with DopaMA was conﬁrmed by
water contact angle measurements and X-ray photoelectron
spectroscopy (XPS) analyses. A statistically signiﬁcant increase
in water contact angle (Figure 3b) was observed upon
DopaMA surface coating, consistent with the increased surface
hydrophobicity due to the bonding of the more hydrophilic
catechol unit with surface oxides, exposing the hydrophobic
methacrylate toward the air. Decreases in XPS signal intensities
for Ti 2p and O 1s and an increase in intensity for C 1s were
also observed upon DopaMA treatment, consistent with the
surface coverage by the organic molecules (Figure 3c).
Hydrogel precursors for PEGDMA-Oligo were then photo-
polymerized onto the DopaMA-coated Ti6Al4V surface. As
shown by dark-ﬁeld optical microscopy (Figure 3d), the
DopaMA intermediate improved the uniformity of the
PEGDMA-Oligo coating on the Ti6Al4V pins (0.5 mm in
diameter; to be inserted into mouse femoral canal in
subsequent in vivo studies). Vancomycin was then covalently
attached to the hydrogel coating by EDC/NHS chemistry as
described earlier. The antibacterial capability of PEGDMA-
Oligo-Vanco-coated Ti6Al4V pins was validated by in vitro
bacterial culture on LB agar plates (Figure S1).
In Vivo Antibacterial Activity of Ti6Al4V Pins Coated
with PEGDMA-Oligo-Vanco Hydrogel. A rodent femoral
canal infection model40,41 was used to investigate the
antibacterial activity of the hydrogel-coated Ti6Al4V IM pins
in vivo. A low dose (40 CFU) of bioluminescent Xen29 S.
aureus was inoculated in the reamed femoral canal of skeletally
mature CL57BL/6 mice (6−10 weeks old, males) before an
unmodiﬁed Ti6Al4V pin, or a Ti6Al4V pin coated with
PEGDMA-Oligo-Vanco or PEGDMA-Oligo hydrogel, was
inserted (Figure S2). Our previous study showed that this
low bacteria inoculation dose was suﬃcient in establishing
infection in the mouse femoral canal.21 The degree of infection
was evaluated with longitudinal IVIS monitoring of the
inoculated bacteria, quantiﬁcation of total bacterial counts on
retrieved pins, longitudinal microcomputed tomography
(μCT) quantiﬁcation of femoral bone changes, and histological
staining of explanted femurs at the 21 day end point.
IVIS detected bioluminescence in the femurs receiving the
IM pins coated with PEGDMA-Oligo control hydrogel at 2
days postoperation which was sustained over the course of 21
days (Figure 4a, bottom panel; Figure 4b, red bars). The
Figure 3. Surface modiﬁcation and characterization of Ti6Al4V plates. (a) Schematic of sequential DopaMA and PEGDMA-Oligo hydrogel
coatings on Ti6Al4V substrates. (b) Water contact angle (n = 6) of Ti6Al4V and Ti6Al4V-DopaMA. Error bars represent standard deviations, ****
p ≤ 0.0001. (c) XPS scans on the Ti6Al4V surfaces before and after DopaMA immobilization. (d) Dark ﬁeld optical micrographs of PEGDMA-
Oligo coating on Ti6Al4V-DopaMA vs Ti6Al4V IM pins (1 mm in diameter). Magniﬁcation: 50×.
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longitudinal detection of bioluminescence in the no-
vancomycin control coating group further validated the
establishment of infection with the inoculation of 40 CFU
Xen29 S. aureus. By stark contrast, no obvious bioluminescence
was visualized from the femurs inserted with the IM pins
coated with PEGDMA-Oligo-Vanco at any time point during
the 21 day follow-up (Figure 4a, bottom panel), and the
quantiﬁcation of bioluminescent signals conﬁrmed signiﬁcant
reduction in intensity by >95% at 2 days postoperation
compared to the control groups (pins with PEGDMA-Oligo
coating, Figure 4b, black bars; or unmodiﬁed pins, Figure S3),
and complete disappearance after day 7 (Figure 4b, red bars).
To conﬁrm the elimination of bacterial burden by the
PEGDMA-Oligo-Vanco coating in vivo, the IM pins were
harvested on day 21 and thoroughly vortexed (5 min in LB
media) before the suspensions were cultured on LB agar plates
for bacterial counts. Consistent with the IVIS imaging data, no
bacteria were recovered from the retrieved IM pins with
PEGDMA-Oligo-Vanco coating, supporting complete erad-
ication of periprosthetically bound bacteria while >500 CFU S.
aureus were recovered from the retrieved IM pins with the
PEGDMA-Oligo control coating (Figure 4c).
μCT imaging was carried out postoperation to conﬁrm the
proper positioning of inserted pins in all groups (Figure S4),
and at the 3 week end point to determine the degree of
infection within the femoral region of interest (ROI).
Established local infections (osteomyelitis) could deteriorate
the bone quality over time, causing decreases in bone volume
fraction (BVF)42 and bone mineral density (BMD),43 and
resulting in cortical thickening44 in the aﬀected area.
Accordingly, these properties were quantiﬁed by end point
μCT in both infected and uninfected femurs treated with IM
pins with or without hydrogel coatings. 3D μCT axial slice
images at the end point revealed osteolysis and an increase in
cortical thickness (C. Th.), most clearly observed in the distal
region of the infected femurs treated with unmodiﬁed pins
(Figure S5a) or pins coated with PEGDMA-Oligo control
hydrogel (Figure 5a). These changes were conﬁrmed by the
signiﬁcant decreases in BVF and BMD accompanying the
increase in C. Th. in the PEGDMA-Oligo + S. aureus group
(Figure 5b) and the unmodiﬁed pin + S. aureus group (Figure
S5b) compared to the uninfected groups or the infected group
treated with pins coated with PEGDMA-Oligo-Vanco. The
PEGDMA-Oligo-Vanco + S. aureus group showed no
signiﬁcant diﬀerences in BVF, BMD, or C. Th. when compared
to uninfected control groups, suggesting that the coating
eﬀectively prevented the changes in bone architecture often
seen in osteomyelitis.
Histological staining of explanted femurs was used to
corroborate the morphological changes observed by μCT and
to visualize any colonization or penetration of bacteria along
the endosteal surface or within the canaliculi of the cortical
bone. Hematoxylin and eosin (H&E) staining revealed normal
cortical bone structure and bone marrow morphology in the
PEGDMA-Oligo-Vanco + S. aureus group while pronounced
cortical thickening was found in the PEGDMA-Oligo control +
S. aureus (Figure 5c) and unmodiﬁed Ti6Al4V + S. aureus
(Figure S6) groups, consistent with μCT ﬁndings. A highly
cellularized bone marrow canal was also detected in the
infected groups treated with unmodiﬁed pins (Figure S6,
bottom row, *) or pins with the PEGDMA-Oligo control
coating (Figure 5c, middle row, *), consistent with elevated
cellular responses to an active local infection. No alkaline
phosphatase (ALP, blue, osteoblasts) or tartrate-resistant acid
phosphatase (TRAP, red, osteoclasts) activities, indicative of
active bone remodeling, were found in the PEGDMA-Oligo-
Vanco + S. aureus group (Figure 5c and Figure S6, top rows)
or the uninfected groups (Figure S6, middle 2 rows). By
contrast, infected femurs treated with unmodiﬁed pins (Figure
S6, bottom row) or pins with the PEGDMA-Oligo control
coating (Figure 5c, middle and bottom rows) exhibited
coupled osteoblastic and osteoclastic activities within the
cortical bone, consistent with the observed cortical thickening
and enhanced remodeling within the cortices. Gram staining
revealed colonized bacteria (blue) within the bone marrow
canal of the PEGDMA-Oligo control + S. aureus (Figure 5c,
middle and bottom rows) and unmodiﬁed pins + S. aureus
groups (Figure S6, bottom row, inset) but not in the
PEGDMA-Oligo-Vanco + S. aureus group (Figure 5c and
Figure S6, top rows) or the control groups without S. aureus
inoculation (Figure S6, 2 middle rows). No bacteria were
detected in the cortical bone canaliculi by optical microscopy.
These μCT and histological ﬁndings strongly corroborated
the bioluminescence data and end point bacterial counts on
the retrieved pins to demonstrate the eﬀectiveness of
PEGDMA-Oligo-Vanco-coated Ti6Al4V pins in eradicating
S. aureus within the marrow canal in a timely manner to
prevent their colonization on the implant surface or invasion
into the cortical bone. These outcomes represent a signiﬁcant
improvement over the short-range suppression of bacterial
colonization on Ti6Al4V IM pins achieved by vancomycin
covalently conjugated to either surface oxides40 or to implant
surface-grafted polymer brushes.21 The on-demand release of
vancomycin from the hydrogel coating enabled the bactericidal
Figure 4. Complete eradication of S. aureus inoculated in the mouse
femoral canal by PEGDMA-Oligo-Vanco coating. (a) IVIS images of
mouse femurs injected with 40 CFU Xen-29 S. aureus and inserted
with IM pins with PEGDMA-Oligo-Vanco or PEGDMA-Oligo
coatings at 2, 7, 14, and 21 days. (b) Quantiﬁcation of longitudinal
bioluminescence signals of mouse femurs injected with 40 CFU Xen-
29 S. aureus and inserted with the diﬀerent hydrogel-coated pins at 2,
7, 14, and 21 days (n = 14). (c) S. aureus recovery from 21 day
explanted pins (n = 11). Error bars represent standard deviations. * p
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 (two-way
ANOVA for part b; Student’s t-test for part c).
ACS Central Science Research Article
DOI: 10.1021/acscentsci.9b00870
ACS Cent. Sci. 2019, 5, 1929−1936
1933
properties of the freed vancomycin to be exerted in the broader
periprosthetic tissue environment in a timely manner, clearing
the bacteria before they had a chance to colonize on implant
surfaces or invade the bone.
Scavenger organs harvested at 21 days postoperation
revealed no diﬀerence among any of the groups treated with
hydrogel-coated pins (both infected and uninfected) versus the
healthy controls (Figure S7), supporting the safety of the
coatings including the subsequently released vancomycin
within the time frame examined. Such a safety proﬁle is not
surprising given that the polymethacrylate chemistry is
employed in commercial bone cements, and the covalent
vancomycin loading dose of 0.6 μg/mg PEGDMA applied to
the Ti6Al4V IM pin was 200−400-fold lower than the
common prophylactic antibiotics loading doses in commercial
bone cement.34−37
Taken together, these in vivo results support outstanding
bactericidal properties of the PEGDMA-Oligo-Vanco coating
applied to Ti6Al4V pins to protect against S. aureus infections,
eradicating the bacteria from both the implant surface and its
periprosthetic bony tissue environment. The low dose of 40
CFU of S. aureus inoculated was suﬃcient to establish infection
in the untreated groups and emulates a realistic clinical setting
where, following standard debridement, gross infections prior
to implantation are unlikely; it supports the validity of this
model for examining the eﬃcacy of prophylactic bactericidal
coatings. By contrast, the literature shows that, in the absence
of an MN-sensitive linker, antibiotics covalently attached to
metallic implants can only reduce the bacterial colonization/
bioﬁlm formation on the implant surface16,21,40 but are unable
to release free-diﬀusing vancomycin to the broader peripros-
thetic tissue space to prevent the invasion, proliferation, and
colonization to tissue and ultimately the development of
chronic infections. A limitation of the current rodent study is
the limited postoperation monitoring duration. To assess the
long-term protection of this coating strategy against
periprosthetic infections and its impact on implant osteointe-
gration, a large animal study employing clinically used metallic
implants, with/without porous surface topography, for up to 6
months would be desired. In addition, examining whether this
coating strategy may be extended to bone cements and dental
resins will also help determine the scope of its potential clinical
translation.
■ CONCLUSIONS
In summary, the PEGDMA-Oligo-Vanco hydrogel coating
applied to the surface of Ti6Al4V eﬀectively prevented S.
aureus colonization on the surface of the implants and
eradicated local infection both in vitro and in vivo. The
vancomycin was cleaved and released from the hydrogel
Figure 5. Prevention of the development of osteomyelitis in mouse femoral canal inoculated with S. aureus by PEGDMA-Oligo-Vanco coating. (a)
3D μCT axial images of the distal femoral region 21 days after the insertion of Ti6Al4V IM pins (pins excluded during contouring) with diﬀerent
hydrogel coatings, with or without the inoculation of 40-CFU Xen-29 S. aureus. (b) Quantiﬁcation of femoral BVF, BMD, and C. Th. of infected
and uninfected femurs 21 days after the insertion of Ti6Al4V IM pins with PEGDMA-Oligo-Vanco or PEGDMA-Oligo coatings. n = 11−14. Error
bars represent standard deviations. * p ≤ 0.05, ** p ≤ 0.01 as compared to the PEGDMA-Oligo control coating + S. aureus group (one-way
ANOVA). (c) H&E, ALP (blue)/TRAP (red), and Gram staining (bacteria stain blue) of explanted femurs in the infected group with PEGDMA-
Oligo-Vanco coating or PEGDMA-Oligo control coating at 21 days postoperation. Dashed lines outline the cortical bone; BM = bone marrow;
BM* = infected bone marrow; arrowheads indicate regions of enhanced ALP/TRAP activities; higher magniﬁcation views of the regions within the
blue and red boxes are shown in the bottom row. Scale bars = 500 μm (top and middle rows) or 100 μm (bottom row).
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coating in the intramedullary space of mouse femurs
inoculated with S. aureus, resulting in timely eradication of S.
aureus from the implant surface and within the marrow cavity
and preventing invasion of bacteria into cortical bone and the
subsequent development of osteomyelitis. Conceptually, our
ﬁndings support that early and timely bactericidal action by
MN-triggered release of antibiotics is an eﬀective prophylactic
method to bypass the notoriously harder to treat periprosthetic
bioﬁlms and osteomyelitis.
From a translational perspective, the PEG-based polyme-
thacrylate gelling mechanism was compatible with the
solidiﬁcation of bone cement and dental resin and, thus, may
be applied as prophylactic standard care to prevent implant-
associated bioﬁlm formation and osteomyelitis. The DopaMA
intermediate coating applied to the metallic implant surfaces
ensures a stable and uniform hydrogel coating on the metallic
implant surface. Finally, the low eﬀective antibiotic tethering
dose (e.g., more than 2 orders of magnitude reduction
compared to prophylactic antibiotics physically blended with
bone cement) and the MN-sensitive on-demand release
mechanism improve both the eﬃcacy (timely release) and
safety of local antibiotics delivery.
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